-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
01 Enterprise situation analysis
Enterprise situation analysisAs of the end of December 2022, a total of 1360797 biomedical enterprises have been established nationwide in 2022, an increase of 12.
04%
over the previous year.
From the perspective of the geographical distribution of new enterprises, the top ten provinces in the number of enterprises are Guangdong Province, Shandong Province, Henan Province, Beijing Municipality, Jiangsu Province, Hunan Province, Anhui Province, Zhejiang Province, Sichuan Province and Yunnan Province, accounting for 57.
24%
of the total number of new enterprises in the country.
The top ten cities in terms of number of enterprises are Beijing, Guangzhou, Shanghai, Shenzhen, Chengdu, Chongqing, Zhengzhou, Hangzhou, Changsha and Jinan, accounting for 23.
34%
of the total number of new enterprises in the country.
Table 1: Top 10 provinces and cities for new enterprises in 2022
Source: Firestone Creation Industry Data Center
02 Analysis of industrial financing
02 Analysis of industrial financingIn 2022, a total of 2,237 financing events occurred in the biomedical field nationwide (excluding proposed acquisitions, acquisitions, fixed additions, and listings), with a cumulative amount of 122.
588 billion yuan
.
From the perspective of the number of financings, the financing events of the biopharmaceutical industry in 2022 were mainly distributed in equity financing, with a total of 1,155 events invested
.
In terms of financing amount, the highest financing amount of Series B financing was 21.
766 billion yuan; secondly, the amount of Series A financing was also more prominent, with a financing amount of 18.
363 billion yuan
.
Table 2: Distribution of health financing events in 2022
Source: Firestone Creation Industry Data Center
In terms of financing regions, financing events in 2022 were mainly distributed in Jiangsu Province (461 cases) and Shanghai (370 cases).
In terms of financing amount, Shanghai is the most prominent, with a financing amount of 241.
86
billion yuan; Secondly, Jiangsu Province is also more prominent, with a financing amount of 20.
779 billion yuan
.
Table 3: Regional distribution of financing events in 2022
Source: Firestone Creation Industry Data Center
From the perspective of financing amount, there were 2,237 financing events in 2022, of which 486 were financing events with a single financing amount of more than 100 million yuan, with a total financing amount of about 114.
096 billion yuan, accounting for 93.
07%
of the total financing scale in 2022.
Figure 1: Distribution of financing amounts in 2022 Source: Firestone Creation Industry Data Center
03 Analysis of listed companies
03 Analysis of listed companiesAs of the end of December 2022, there were 1,385 biopharmaceutical listed enterprises in the country, and compared with the same period of the previous year, 111 new listed biopharmaceutical enterprises were added in 2022
.
The market distribution is 25 listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, 4 listed on the main board of the Shanghai Stock Exchange, 23 listed on the Growth Enterprise Market of the Shenzhen Stock Exchange, 5 listed on the Beijing Stock Exchange, 27 listed on the New Third Board, 3 listed on the Old Third Board and 24 listed on the Main Board of the Hong Kong Stock Exchange
.
The total market value of listed biopharmaceutical enterprises in China reached 12.
14 trillion yuan
.
Among them, there are 14 biopharmaceutical listed enterprises with a market value of more than 100 billion yuan, distributed in innovative drugs, medical devices, medical services and other fields
.
Table 4: Top 10 biopharmaceutical companies by market capitalization in 2022
Source: Firestone Creation Industry Data Center
Table 5: List of biopharmaceutical listed companies in 2022
Source: Firestone Creation Industry Data Center
Compared with the same period of the previous year, Recon, Beyikang, Zhongju Stomatology, Shuangfeiren, and Aoluxin all showed a double growth, of which the market value of Reelkang (839881) increased by 7688.
46%, and the market value of Beyikang (870199) increased by 3300.
56%; Heath Medical Beauty, Yunnan Traditional Chinese Medicine, Hengyuan Pharmaceutical, Hongxianglong and Fujian Taier fell significantly, of which the market value of Heath Medical Beauty (871107) fell by 96.
81%, and the market value of Yunnan Traditional Chinese Medicine (839782) fell by 91.
13%.
Table 6: Top 5 biopharmaceutical companies in 2022
Source: Firestone Creation Industry Data Center
04 Analysis of drug clinical trials
04 Analysis of drug clinical trialsIn 2022, a total of 2,805 products were approved for clinical trials nationwide, an increase of 4.
7%
compared with 2021.
Among them, there are 995 in the field of biological drugs, 43 in the field of traditional Chinese medicine, and 1767 in the field of chemical medicine
.
From the perspective of clinical trial companies, the clinical trials approved this year came from 676 companies, of which Eli Lilly was the most approved, with 43 clinical approvals, followed by Pfizer with 42 clinical approvals
.
From the clinical trial stage, there are 856 phase I clinical trials, 520 phase II clinical trials, 411 phase III clinical trials and 51 phase IV clinical trials
.
Among the 411 phase III clinical trial projects, according to clinical trial sponsors, the number of phase III clinical trials applied for is basically related to the overall strength of each company, and some giant pharmaceutical companies are in the front
.
Novartis
Pharma registered the most, with 28 projects; This is followed by AstraZeneca with 21 projects
.
In addition, Eli Lilly and Company and Merck Sharp
& Dohme B.
V.
has also conducted 18 phase III clinical trials
.
Figure 2: 2022 Phase III.
Clinical Trial Sponsors TOP23 Source: Firestone Creation Industry Data Center
According to the name of the drug, the number of phase III clinical trial projects was the largest, all of which were 4 with Depemokimab injection, lyophilized human rabies vaccine (Vero cells), pembrolizumab injection and DS-1062a for injection
.
There are 19 drugs with 3 phase III.
clinical trials greater than or equal
.
Figure 3: Top 19 drugs in phase III.
clinical trials in 2022 Source: Firestone Creation Industry Data Center
05 Analysis of drug approval
05 Analysis of drug approvalIn 2022, a total of 1,129 products were approved for marketing nationwide, a decrease of 8.
8%
compared with 2021.
It has 1,004 drugs produced in China and 125 imported drugs
.
From the perspective of drug types, there are 53 in the field of biological drugs, 16 in the field of traditional Chinese medicine, and 1060 in the field of chemical drugs
.
This year, the State Medical Products Administration approved a total of 145 new drugs for marketing, including 30 Class 1 new drugs
.
Table 7: Class 1 new drugs approved by the State Medical Products Administration in 2022
Source: Firestone Creation Industry Data Center
In 2022, 68 medicines were included in the priority review process
by the CDE.
Table 8: Varieties approved by the CDE for priority review in 2022
Source: Firestone Creation Industry Data Center
06 Analysis of medical device approval
06 Analysis of medical device approvalIn 2022, a total of 43,370 medical devices across the country were approved for marketing for the first time, including 42,028 Chinese-made devices and 1,342 imported devices
.
From the perspective of product registration classification, there are 2172 Class 3 medical devices, 13405 Class 2 medical devices, and 27793 Class 1 medical devices
.
From the perspective of the geographical distribution of approved products, the top ten provinces approved for Class 3 devices are Jiangsu Province, Guangdong Province, Beijing Municipality, Shanghai Municipality, Zhejiang Province, Shandong Province, Tianjin Municipality, Fujian Province, Sichuan Province, Chongqing Municipality, accounting for 87.
48%
of the total number of new Class 3 device products in China.
The top ten cities approved for Class 3 devices are Beijing, Shenzhen, Shanghai, Suzhou, Tianjin, Changzhou, Hangzhou, Guangzhou, Nanjing and Xiamen, accounting for 61.
84%
of the total number of new Class 3 equipment products in China.
Table 9: Top 10 provinces and cities with medical devices approved for the first time in 2022
Source: Firestone Creation Industry Data Center
In 2022, a total of 117 products will enter the priority approval channel, and a total of 108 products will enter the special review and approval channel
.
Table 10: Products approved for inclusion in priority and special approvals in 2022
Source: Firestone Creation Industry Data Center
